$AMPE @topshear "According to Michael Macaluso, Ampio CEO, “The Company has identified and engaged 15 clinical sites for the trial (AP-013) and patient identification is underway. This pivotal trial seeks to enroll approximately 1,000 patients, with an interim look, to allow sample size adjustments, if required. This trial will assess co-primary endpoints of pain and function. More details of the study will be made available on clinicaltrials.gov/.” Do you notice the words "SAMPLE SIZE ADJUSTMENTS" That blows your 724 right into the wind. So run along until you read and actually comprehend the words.